⌘K
t
Roquefort Therapeutics plc appointed SP Angel Corporate Finance LLP as its broker. This appointment took effect immediately on 20 June 2024.
| Date | 20 Jun 2024 |
| Time | 07:00:10 |
| Category | Corporate updates |
| ID | 1220T |
20 June 2024
Roquefort Therapeutics plc
("Roquefort Therapeutics")
Appointment of Broker
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immuno-oncology market, is pleased to announce the appointment of SP Angel Corporate Finance LLP as its broker with immediate effect.
-ENDS-
Enquiries:
|
Roquefort Therapeutics plc |
+44 (0)20 3918 8633 |
|
Stephen West (Chairman) / Ajan Reginald (CEO) |
|
|
SP Angel Corporate Finance LLP (Broker) Jeff Keating / David Hignell / Vadim Alexandre
|
+44 (0) 20 3470 0470
|
|
Buchanan (Public Relations) Ben Romney / Jamie Hooper / George Beale
|
+44 (0)20 7466 5000
|
|
Peak IR (Investor Relations) Seb Wykeham |
+33 (0)7 44 44 15 42 |
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market listed biotech company developing first in class drugs in the high value and high growth immuno-oncology segment prior to partnering or selling to big pharma.
Roquefort Therapeutics' portfolio consists of five novel, patent-protected pre-clinical anti-cancer medicines. The highly complementary profile of five best-in-class medicines consists of:
· Midkine antibodies with significant in vivo efficacy and toxicology studies;
· Midkine RNA therapeutics with novel anti-cancer gene editing action;
· Midkine mRNA therapeutics with novel anti-cancer approach;
· STAT-6 siRNA therapeutics targeting solid tumours with significant in vivo efficacy; and
· MK cell therapy with direct and NK-mediated anti-cancer action
For further information on Roquefort Therapeutics, please visit www.roquefortplc.com and @RoquefortTherap on X (formerly Twitter).